Jubilant Pharmova Limited (NSE:JUBLPHARMA) — Market Cap & Net Worth

$1.60 Billion USD  · Rs148.12 Billion INR  · Rank #6846

Market Cap & Net Worth: Jubilant Pharmova Limited (JUBLPHARMA)

Jubilant Pharmova Limited (NSE:JUBLPHARMA) has a market capitalization of $1.60 Billion (Rs148.12 Billion) as of August 1, 2026. Listed on the NSE stock exchange, this India-based company holds position #6846 globally and #334 in its home market, demonstrating a -3.67% decrease in market value over the past year.

Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jubilant Pharmova Limited's stock price Rs935.15 by its total outstanding shares 158387168 (158.39 Million). See Jubilant Pharmova Limited capex to cash flow ratio to understand how much of operating cash flow is reinvested back into capital assets.

Jubilant Pharmova Limited Market Cap History: 2015 to 2026

Jubilant Pharmova Limited's market capitalization history from 2015 to 2026. Data shows growth from $564.68 Million to $1.60 Billion (10.71% CAGR).

Index Memberships

Jubilant Pharmova Limited is a constituent of 5 market indices:

Index Total Market Cap Weight (%) Rank by Market Cap
NIFTY 500
NIFTY500
$3.17 Trillion 0.05% #287 of 500
NIFTY ALHPA 50
NIFTYALI
$359.91 Billion 0.45% #24 of 47
NIFTY MIDSMALLCAP 400
NIFTYMIDSML400
$1.15 Trillion 0.14% #196 of 400
NIFTY TOTAL MARKET
NIFTYTOTALMKT
$3.26 Trillion 0.05% #289 of 750
NIFTY SMALLCAP 250
NISM250
$392.18 Billion 0.41% #102 of 250

Weight: Jubilant Pharmova Limited's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.

Jubilant Pharmova Limited Market Cap to Earnings & Revenue Ratios Timeline

This chart shows how Jubilant Pharmova Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.

Latest Price to Sales (P/S) Ratio

0.03x

Jubilant Pharmova Limited's market cap is 0.03 times its annual revenue

Industry average: 0.63x Lower than industry average

Latest Price to Earnings (P/E) Ratio

0.22x

Jubilant Pharmova Limited's market cap is 0.22 times its annual earnings

Industry average: 4.55x Lower than industry average

What These Ratios Tell Investors:

  • Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
  • Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
  • Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
  • Industry comparison provides context for whether the company is valued higher or lower than peers.
Year Market Cap (USD) Revenue (USD) Net Income (USD) P/S Ratio P/E Ratio
2016 $865.85 Million $57.49 Billion $3.92 Billion 0.02x 0.22x
2017 $1.09 Billion $58.61 Billion $5.76 Billion 0.02x 0.19x
2018 $989.00 Million $75.18 Billion $6.43 Billion 0.01x 0.15x
2019 $757.07 Million $91.11 Billion $5.74 Billion 0.01x 0.13x
2020 $1.20 Billion $59.76 Billion $8.98 Billion 0.02x 0.13x
2021 $970.90 Million $60.99 Billion $8.36 Billion 0.02x 0.12x
2022 $630.31 Million $61.30 Billion $4.14 Billion 0.01x 0.15x
2023 $927.51 Million $62.82 Billion -$610.00 Million 0.01x N/A
2024 $1.89 Billion $67.03 Billion $771.00 Million 0.03x 2.46x
2025 $1.84 Billion $72.34 Billion $8.39 Billion 0.03x 0.22x

Competitor Companies of JUBLPHARMA by Market Capitalization

Companies near Jubilant Pharmova Limited in the global market cap rankings as of August 1, 2026.

Key companies related to Jubilant Pharmova Limited by market ranking:

  • Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #503 globally with a market cap of $52.60 Billion USD.
  • Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #528 globally with a market cap of $50.48 Billion USD ( CN¥344.98 Billion CNY).
  • GALDERMA GROUP AG (NYSE:GALDY): Ranked #550 globally with a market cap of $48.78 Billion USD.
  • Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
Market capitalization comparison (in billions USD)
Rank Company Symbol Market Cap Price
#503 Takeda Pharmaceutical Co Ltd ADR NYSE:TAK $52.60 Billion $16.65
#528 Jiangsu Hengrui Medicine Co Ltd SHG:600276 $50.48 Billion CN¥54.08
#550 GALDERMA GROUP AG NYSE:GALDY $48.78 Billion $43.60
#619 Takeda Pharmaceutical Company Limited F:TKDA $43.60 Billion €15.50

Jubilant Pharmova Limited Historical Marketcap From 2015 to 2026

Between 2015 and today, Jubilant Pharmova Limited's market cap moved from $564.68 Million to $ 1.60 Billion, with a yearly change of 10.71%.

Year Market Cap Change (%)
2026 Rs1.60 Billion -12.87%
2025 Rs1.84 Billion -2.89%
2024 Rs1.89 Billion +104.11%
2023 Rs927.51 Million +47.15%
2022 Rs630.31 Million -35.08%
2021 Rs970.90 Million -19.19%
2020 Rs1.20 Billion +58.70%
2019 Rs757.07 Million -23.45%
2018 Rs989.00 Million -9.52%
2017 Rs1.09 Billion +26.24%
2016 Rs865.85 Million +53.33%
2015 Rs564.68 Million --

End of Day Market Cap According to Different Sources

On Aug 1st, 2026 the market cap of Jubilant Pharmova Limited was reported to be:

Source Market Cap
Yahoo Finance $1.60 Billion USD
MoneyControl $1.60 Billion USD
MarketWatch $1.60 Billion USD
marketcap.company $1.60 Billion USD
Reuters $1.60 Billion USD

Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.

About Jubilant Pharmova Limited

NSE:JUBLPHARMA India Drug Manufacturers - Specialty & Generic
Market Cap
$1.60 Billion
Rs148.12 Billion INR
Market Cap Rank
#6846 Global
#334 in India
Share Price
Rs935.15
Change (1 day)
-2.76%
52-Week Range
Rs807.65 - Rs1181.20
All Time High
Rs1269.00
About

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment o… Read more